News Categories Arthritis Autoimmunity BioPharm Business Bones Consumer News Imaging Pain Procedures Skin Spondyloarthropathies
Meeting Highlights
ISEMIR 2009: Video coverage of the Meeting
Miami, March 27, 2009
Miami, March 27, 2009
RWCS 2009: Video coverage of the Symposium
Maui, January 14-17, 2009
Maui, January 14-17, 2009
ACR 2008: News from the Annual Scientific Meeting
San Francisco, October 24-29, 2008
San Francisco, October 24-29, 2008
EULAR 2008: Coverage of the Congress
Paris, June 11-14, 2008
Paris, June 11-14, 2008
ISEMIR 2008: Video coverage of the Meeting
Chicago, April 10, 2008
Chicago, April 10, 2008
AAOS 2008: News from the Annual Meeting
San Francisco, March 5-9, 2008
San Francisco, March 5-9, 2008
- E-mail article
- Print-Friendly
Drugs to Build Bones May Weaken Them
July 17, 2008
The bisphosphonate class of drugs, which are used to improve bone health, recently became controversial when data emerged showing the drugs can lead to severe bone, joint, or musculoskeletal pain. Now new cases have come to light that further complicate the controversy over using bisphosphonates to prevent and treat osteoporosis. A series of case reports describe unusual leg fractures, in which the upper thighbone breaks straight across, despite little or no trauma being suffered. Such fractures are rare, and are typically only suffered after car accidents or similar traumas, or in elderly and frail individuals. The cases that were being reported, however, were in patients who had been taking bisphosphonates to promote bone building for 5 or more years. Some of the patients experienced unexplained aches before their thighbones simply snapped. In these cases, the bisphosphonates appear to have been weakening the patients’ bones, rather than slowing the process of bone thinning, as the drug is designed to do. Researchers studying the cases are emphasizing that this is a rare problem, and there is not enough data to suggest the prevention of use of bisphosphonates to treat osteoporosis. These cases may lead some doctors to rethink how much they should rely on this class of drugs as preventative medicine, however. Since all of the fractures occurred in patients taking the drug for 5 or more years, this information may also influence prescribing long-term use of bisphosphonates in the future.
Read the full text of this article
Please rate the relevance of this article to your practice:
Please rate the importance of other doctors being aware of this article:
more news »
News Categories:
Arthritis | Autoimmunity | BioPharm Business | Bones | Imaging | Procedures | Skin | Spondyloarthropathies
Events:
ACR 2007 | ASBMR 2007 | EULAR 2007 | GARN 2007 | LUPUS 2007 | EULAR 2006 | ACR 2006 | ORS 2006 | OARSI 2006
CME:
Publications:
About Us: